2019 Q4 Form 10-Q Financial Statement

#000135657619000045 Filed on November 08, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2018 Q4
Revenue $100.4M $102.1M $115.9M
YoY Change -13.36% -0.83% 31.15%
Cost Of Revenue $4.100M $4.819M $4.200M
YoY Change -2.38% 14.55% 0.0%
Gross Profit $96.30M $97.32M $111.7M
YoY Change -13.79% -1.49% 32.5%
Gross Profit Margin 95.87% 95.28% 96.35%
Selling, General & Admin $35.70M $39.34M $42.10M
YoY Change -15.2% -3.79% 24.56%
% of Gross Profit 37.07% 40.43% 37.69%
Research & Development $19.80M $16.94M $29.80M
YoY Change -33.56% -17.04% 83.95%
% of Gross Profit 20.56% 17.41% 26.68%
Depreciation & Amortization $1.700M $1.600M $1.700M
YoY Change 0.0% -15.79% 6.25%
% of Gross Profit 1.77% 1.64% 1.52%
Operating Expenses $55.50M $56.29M $71.90M
YoY Change -22.81% -8.2% 44.09%
Operating Profit $40.82M $39.73M $39.86M
YoY Change 2.41% 6.01% 15.86%
Interest Expense -$3.300M $5.662M $100.0K
YoY Change -3400.0% 5562.0% -88.89%
% of Operating Profit -8.09% 14.25% 0.25%
Other Income/Expense, Net $3.400M -$139.0K -$1.200M
YoY Change -383.33% -87.41% 500.0%
Pretax Income $40.90M $39.59M $38.80M
YoY Change 5.41% 8.85% 10.54%
Income Tax $7.800M $10.73M $12.90M
% Of Pretax Income 19.07% 27.1% 33.25%
Net Earnings $33.13M $28.86M $25.89M
YoY Change 27.95% 3.03% 89.0%
Net Earnings / Revenue 32.98% 28.26% 22.33%
Basic Earnings Per Share $0.63 $0.55 $0.50
Diluted Earnings Per Share $0.62 $0.54 $0.48
COMMON SHARES
Basic Shares Outstanding 52.46M shares 52.45M shares
Diluted Shares Outstanding 53.81M shares

Balance Sheet

Concept 2019 Q4 2019 Q3 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $347.1M $296.7M $356.0M
YoY Change -2.5% 5.89% 154.29%
Cash & Equivalents $181.4M $116.9M $192.2M
Short-Term Investments $165.7M $179.8M $163.8M
Other Short-Term Assets $11.60M $18.20M $8.900M
YoY Change 30.34% 95.7% 36.92%
Inventory $26.63M $25.50M $25.66M
Prepaid Expenses
Receivables $87.33M $86.70M $102.9M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $472.6M $427.1M $493.5M
YoY Change -4.22% 9.34% 115.97%
LONG-TERM ASSETS
Property, Plant & Equipment $17.07M $9.977M $4.095M
YoY Change 316.8% 44.59% -19.71%
Goodwill $0.00
YoY Change
Intangibles $24.84M $26.10M $31.37M
YoY Change -20.81%
Long-Term Investments $591.8M $596.4M $418.8M
YoY Change 41.31% 29.57% 213.47%
Other Assets $21.89M $574.0K $380.0K
YoY Change 5661.58% -98.21% -98.21%
Total Long-Term Assets $687.6M $679.8M $484.3M
YoY Change 41.98% 27.81% 147.1%
TOTAL ASSETS
Total Short-Term Assets $472.6M $427.1M $493.5M
Total Long-Term Assets $687.6M $679.8M $484.3M
Total Assets $1.160B $1.107B $977.8M
YoY Change 18.66% 19.99% 130.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.14M $3.090M $3.195M
YoY Change 217.4% -68.47% -53.01%
Accrued Expenses $49.71M $138.9M $36.54M
YoY Change 36.07% 17.61% -61.78%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $160.6M $149.7M $161.4M
YoY Change -0.47% 8.26% 31.18%
LONG-TERM LIABILITIES
Long-Term Debt $345.2M $341.2M $329.5M
YoY Change 4.76% 4.76%
Other Long-Term Liabilities $28.66M $11.21M $11.40M
YoY Change 151.42% -69.37% -66.48%
Total Long-Term Liabilities $28.66M $11.21M $11.40M
YoY Change 151.42% -96.91% -66.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $160.6M $149.7M $161.4M
Total Long-Term Liabilities $28.66M $11.21M $11.40M
Total Liabilities $564.9M $549.7M $524.8M
YoY Change 7.63% 9.8% 234.26%
SHAREHOLDERS EQUITY
Retained Earnings $199.5M $166.4M $86.49M
YoY Change 130.71%
Common Stock $53.00K $52.00K $52.00K
YoY Change 1.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $595.4M $557.3M $453.0M
YoY Change
Total Liabilities & Shareholders Equity $1.160B $1.107B $977.8M
YoY Change 18.66% 19.99% 130.34%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2018 Q4
OPERATING ACTIVITIES
Net Income $33.13M $28.86M $25.89M
YoY Change 27.95% 3.03% 89.0%
Depreciation, Depletion And Amortization $1.700M $1.600M $1.700M
YoY Change 0.0% -15.79% 6.25%
Cash From Operating Activities $43.80M $37.60M $32.90M
YoY Change 33.13% -39.74% -9.37%
INVESTING ACTIVITIES
Capital Expenditures -$2.000M -$500.0K -$100.0K
YoY Change 1900.0% 400.0% -85.71%
Acquisitions
YoY Change
Other Investing Activities $21.50M -$7.900M $34.50M
YoY Change -37.68% -130.98% -287.5%
Cash From Investing Activities $19.50M -$8.400M $34.30M
YoY Change -43.15% -133.2% -279.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.200M 300.0K 1.200M
YoY Change 0.0% -62.5% 0.0%
NET CHANGE
Cash From Operating Activities 43.80M 37.60M 32.90M
Cash From Investing Activities 19.50M -8.400M 34.30M
Cash From Financing Activities 1.200M 300.0K 1.200M
Net Change In Cash 64.50M 29.50M 68.40M
YoY Change -5.7% -66.67% 271.74%
FREE CASH FLOW
Cash From Operating Activities $43.80M $37.60M $32.90M
Capital Expenditures -$2.000M -$500.0K -$100.0K
Free Cash Flow $45.80M $38.10M $33.00M
YoY Change 38.79% -39.04% -10.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Entity Central Index Key
EntityCentralIndexKey
0001356576
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52316583 shares
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52462936 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52316583 shares
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52462936 shares
CY2019Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0 USD
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2019-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35518
dei Entity Registrant Name
EntityRegistrantName
SUPERNUS PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-2590184
dei Entity Address Address Line1
EntityAddressAddressLine1
1550 East Gude Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Rockville 
dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20850
dei City Area Code
CityAreaCode
301
dei Local Phone Number
LocalPhoneNumber
838-2500
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52462936 shares
CY2018Q4 us-gaap Inventory Net
InventoryNet
25659000 USD
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18182000 USD
dei Trading Symbol
TradingSymbol
SUPN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
116889000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192248000 USD
CY2019Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
179808000 USD
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
163770000 USD
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
86699000 USD
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
102922000 USD
CY2019Q3 us-gaap Inventory Net
InventoryNet
25504000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8888000 USD
CY2019Q3 us-gaap Assets Current
AssetsCurrent
427082000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
493487000 USD
CY2019Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
596442000 USD
CY2018Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
418798000 USD
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9977000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4095000 USD
CY2019Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
26101000 USD
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
31368000 USD
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18780000 USD
CY2019Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
27953000 USD
CY2018Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
29683000 USD
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
574000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
380000 USD
CY2019Q3 us-gaap Assets
Assets
1106909000 USD
CY2018Q4 us-gaap Assets
Assets
977811000 USD
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3090000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3195000 USD
CY2019Q3 supn Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
98050000 USD
CY2018Q4 supn Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
107063000 USD
CY2019Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
40800000 USD
CY2018Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
36535000 USD
CY2019Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4818000 USD
CY2018Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
12377000 USD
CY2019Q3 supn Non Recourse Debt Sale Of Future Royalties Current
NonRecourseDebtSaleOfFutureRoyaltiesCurrent
2959000 USD
CY2018Q4 supn Non Recourse Debt Sale Of Future Royalties Current
NonRecourseDebtSaleOfFutureRoyaltiesCurrent
2183000 USD
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
149717000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
161353000 USD
CY2019Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
341163000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
39729000 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
37475000 USD
CY2018Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
329462000 USD
CY2019Q3 supn Non Recourse Debt Sale Of Future Royalties Noncurrent
NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent
20305000 USD
CY2018Q4 supn Non Recourse Debt Sale Of Future Royalties Noncurrent
NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent
22575000 USD
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27256000 USD
CY2019Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
11211000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
11398000 USD
CY2019Q3 us-gaap Liabilities
Liabilities
549652000 USD
CY2018Q4 us-gaap Liabilities
Liabilities
524788000 USD
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
52000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
52000 USD
CY2019Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
383525000 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
369637000 USD
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
7261000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3158000 USD
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
166419000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
86492000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
557257000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
453023000 USD
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1106909000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
977811000 USD
CY2019Q3 us-gaap Revenues
Revenues
102140000 USD
CY2018Q3 us-gaap Revenues
Revenues
102996000 USD
us-gaap Revenues
Revenues
292309000 USD
us-gaap Revenues
Revenues
292963000 USD
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4819000 USD
CY2018Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4207000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12547000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11168000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16943000 USD
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20422000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49307000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
59368000 USD
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
40649000 USD
CY2018Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
40892000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
122700000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
117838000 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
62411000 USD
CY2018Q3 us-gaap Costs And Expenses
CostsAndExpenses
65521000 USD
us-gaap Costs And Expenses
CostsAndExpenses
184554000 USD
us-gaap Costs And Expenses
CostsAndExpenses
188374000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
107755000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
104589000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16309000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-139000 USD
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1104000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1180000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3180000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
39590000 USD
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
36371000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
106575000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
101409000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10730000 USD
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8360000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26648000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
28860000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
28011000 USD
us-gaap Net Income Loss
NetIncomeLoss
79927000 USD
us-gaap Net Income Loss
NetIncomeLoss
85100000 USD
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.55
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.64
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.54
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.57
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52453384 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52227630 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52392232 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51897240 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53805838 shares
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54239847 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53898486 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54098330 shares
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
28860000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
28011000 USD
us-gaap Net Income Loss
NetIncomeLoss
79927000 USD
us-gaap Net Income Loss
NetIncomeLoss
85100000 USD
CY2019Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1337000 USD
CY2018Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
8000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
10419000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-3364000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1337000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3364000 USD
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
8000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
10419000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
90346000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
81736000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
453023000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3287000 USD
CY2019Q1 supn Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
783000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
18340000 USD
CY2019Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
4585000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
480018000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
30197000 USD
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
28019000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4022000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1377000 USD
CY2019Q2 supn Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
263000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
32727000 USD
CY2019Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
4497000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
522904000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3914000 USD
CY2019Q3 supn Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
242000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
28860000 USD
CY2019Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1337000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
557257000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
267480000 USD
CY2018Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1
269802000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2635000 USD
CY2018Q1 supn Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
2858000 USD
CY2018Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
56215000 USD
CY2018Q1 supn Purchases Of Convertible Note Hedges Net Of Tax
PurchasesOfConvertibleNoteHedgesNetOfTax
-70137000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
65688000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
26352000 USD
CY2018Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1544000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
351869000 USD
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3068000 USD
CY2018Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1184000 USD
CY2018Q2 supn Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
5462000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
30737000 USD
CY2018Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1828000 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
390492000 USD
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2597000 USD
CY2018Q3 supn Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
828000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
28011000 USD
supn Interest Expense Non Recourse Royalty Liability
InterestExpenseNonRecourseRoyaltyLiability
4331000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
748000 USD
CY2018Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
8000 USD
supn Noncash Operating Lease Cost
NoncashOperatingLeaseCost
2600000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1825000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
11701000 USD
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
421936000 USD
us-gaap Profit Loss
ProfitLoss
79927000 USD
us-gaap Profit Loss
ProfitLoss
85100000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5029000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5371000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
8052000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
3189000 USD
supn Interest Expense Non Recourse Royalty Liability
InterestExpenseNonRecourseRoyaltyLiability
3096000 USD
supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
5028000 USD
supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
4300000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
11223000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
8300000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1689000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-6233000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-16344000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10687000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-155000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6976000 USD
supn Increase Decrease In Prepaid Deferred Expense And Other Current Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets
4236000 USD
supn Increase Decrease In Prepaid Deferred Expense And Other Current Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets
2778000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
141000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
342000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-334000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3066000 USD
supn Increase Decrease In Accrued Product Returns And Rebates
IncreaseDecreaseInAccruedProductReturnsAndRebates
-9013000 USD
supn Increase Decrease In Accrued Product Returns And Rebates
IncreaseDecreaseInAccruedProductReturnsAndRebates
17627000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1120000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5966000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-7559000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-7390000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1903000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
90000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
99338000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
96137000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
361121000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
491654000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
184467000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
45271000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
707000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
679000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-177362000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-447810000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
402500000 USD
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0 USD
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
10435000 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
65688000 USD
supn Purchases Of Convertible Note Hedge
PurchasesOfConvertibleNoteHedge
0 USD
supn Purchases Of Convertible Note Hedge
PurchasesOfConvertibleNoteHedge
92897000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2665000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10331000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2665000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
375187000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-75359000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23514000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
192248000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100304000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
116889000 USD
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
123818000 USD
us-gaap Interest Paid Net
InterestPaidNet
2516000 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
35933000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
29930000 USD
supn Non Cash Capitalized Cost Of Intangible Assets
NonCashCapitalizedCostOfIntangibleAssets
495000 USD
supn Non Cash Capitalized Cost Of Intangible Assets
NonCashCapitalizedCostOfIntangibleAssets
280000 USD
supn Property And Equipment Acquired Under Build To Suit Lease Transaction
PropertyAndEquipmentAcquiredUnderBuildToSuitLeaseTransaction
0 USD
supn Property And Equipment Acquired Under Build To Suit Lease Transaction
PropertyAndEquipmentAcquiredUnderBuildToSuitLeaseTransaction
2304000 USD
supn Interest Capitalized During Construction Period For Build To Suit Lease Transaction
InterestCapitalizedDuringConstructionPeriodForBuildToSuitLeaseTransaction
0 USD
supn Interest Capitalized During Construction Period For Build To Suit Lease Transaction
InterestCapitalizedDuringConstructionPeriodForBuildToSuitLeaseTransaction
44000 USD
supn Facility Lease Financing Obligation
FacilityLeaseFinancingObligation
0 USD
supn Facility Lease Financing Obligation
FacilityLeaseFinancingObligation
2347000 USD
us-gaap Nature Of Operations
NatureOfOperations
<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Business</span></div><div style="line-height:120%;padding-top:13px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supernus Pharmaceuticals, Inc. (the Company) was incorporated in Delaware and commenced operations in 2005. The Company is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> products: Oxtellar XR for the treatment of epilepsy, and Trokendi XR for the prophylaxis of migraine headache and treatment of epilepsy. The Company has several proprietary product candidates in clinical development that address opportunities in the CNS market.</span></div><div style="line-height:120%;padding-top:13px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company launched Oxtellar XR and Trokendi XR for the treatment of epilepsy in 2013, launched Trokendi XR for the prophylaxis of migraine headache in adolescents and adults in April 2017, and launched Oxtellar XR with an expanded indication to include monotherapy for partial seizures in January 2019.</span></div>
supn Number Of Proprietary Commercial Products
NumberOfProprietaryCommercialProducts
2 product
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:13px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company bases its estimates on: historical experience; various forecasts; information received from its service providers; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company evaluates the methodologies employed in its estimates on an ongoing basis.</span></div>
CY2019Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0 USD
supn Sales Return Period Prior To Expiration
SalesReturnPeriodPriorToExpiration
P6M
supn Sales Return Period
SalesReturnPeriod
P12M
supn Number Of Commercial Products
NumberOfCommercialProducts
2 product
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
supn Threshold Limit For Medical Claim
ThresholdLimitForMedicalClaim
150000 USD
CY2019Q3 supn Self Insurance Liability
SelfInsuranceLiability
500000 USD
CY2019Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
766570000 USD
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
586726000 USD
CY2019Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
9756000 USD
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
55000 USD
CY2019Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
76000 USD
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4213000 USD
CY2019Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
776250000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
582568000 USD
CY2019Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
179808000 USD
CY2019Q3 supn Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
194063000 USD
CY2019Q3 supn Available For Sale Securities Debt Maturities Two Years Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesTwoYearsThroughThreeYearsFairValue
201889000 USD
CY2019Q3 supn Available For Sale Securities Debt Maturities Three Years Through Four Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesThreeYearsThroughFourYearsFairValue
200490000 USD
CY2019Q3 supn Available For Sale Securities Debt Maturities Thereafter Fair Value
AvailableForSaleSecuritiesDebtMaturitiesThereafterFairValue
0 USD
CY2019Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
776250000 USD
CY2019Q3 us-gaap Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
5271000 USD
CY2018Q4 us-gaap Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
5742000 USD
CY2019Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
7050000 USD
CY2018Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
7275000 USD
CY2019Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
13183000 USD
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
12642000 USD
CY2019Q3 us-gaap Inventory Net
InventoryNet
25504000 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
25659000 USD
CY2019Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22307000 USD
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15314000 USD
CY2019Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12330000 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11219000 USD
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9977000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4095000 USD
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1100000 USD
CY2018Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1500000 USD
CY2019Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
40800000 USD
CY2018Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
36535000 USD
CY2019Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
17274000 USD
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
13356000 USD
CY2019Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
26101000 USD
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
31368000 USD
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3900000 USD
CY2018Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3900000 USD
CY2019Q3 supn Accrued Clinical Trial And Clinical Supply Costs Current
AccruedClinicalTrialAndClinicalSupplyCostsCurrent
17332000 USD
CY2018Q4 supn Accrued Clinical Trial And Clinical Supply Costs Current
AccruedClinicalTrialAndClinicalSupplyCostsCurrent
14034000 USD
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12820000 USD
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13546000 USD
CY2019Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4003000 USD
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3706000 USD
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3145000 USD
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 USD
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3500000 USD
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5249000 USD
CY2019Q3 supn Accrued Rebates
AccruedRebates
76758000 USD
CY2018Q4 supn Accrued Rebates
AccruedRebates
85003000 USD
CY2019Q3 supn Accrued Product Returns
AccruedProductReturns
21292000 USD
CY2018Q4 supn Accrued Product Returns
AccruedProductReturns
22060000 USD
CY2019Q3 supn Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
98050000 USD
CY2018Q4 supn Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
107063000 USD
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.9063
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.9063
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.9063
CY2019Q3 us-gaap Interest Income Other
InterestIncomeOther
5523000 USD
CY2018Q3 us-gaap Interest Income Other
InterestIncomeOther
4461000 USD
us-gaap Interest Income Other
InterestIncomeOther
15657000 USD
us-gaap Interest Income Other
InterestIncomeOther
9331000 USD
CY2019Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
4546000 USD
CY2018Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
4374000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
13425000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
9415000 USD
CY2019Q3 us-gaap Interest Expense Other
InterestExpenseOther
1116000 USD
CY2018Q3 us-gaap Interest Expense Other
InterestExpenseOther
1191000 USD
us-gaap Interest Expense Other
InterestExpenseOther
3412000 USD
us-gaap Interest Expense Other
InterestExpenseOther
3096000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-139000 USD
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1104000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1180000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3180000 USD
CY2019Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4000000.0 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
11700000 USD
CY2018Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3700000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
8100000 USD
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3914000 USD
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2597000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11223000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8300000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
28860000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
28011000 USD
us-gaap Net Income Loss
NetIncomeLoss
79927000 USD
us-gaap Net Income Loss
NetIncomeLoss
85100000 USD
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52453384 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52227630 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52392232 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51897240 shares
CY2019Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1352454 shares
CY2018Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2012217 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1506254 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2201090 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53805838 shares
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54239847 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53898486 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54098330 shares
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.55
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.64
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.54
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.57
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10730000 USD
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8360000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26648000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16309000 USD
CY2019Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.2710
CY2018Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.2300
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.2500
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.1610
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18780000 USD
CY2019Q3 supn Tenant Receivable Leases Additional Allowance For Tenant And Capital Improvement
TenantReceivableLeasesAdditionalAllowanceForTenantAndCapitalImprovement
4096000 USD
CY2019Q3 supn Lessee Operating Lease Assets
LesseeOperatingLeaseAssets
22876000 USD
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3145000 USD
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27256000 USD
CY2019Q3 supn Lessee Operating Lease Liabilities
LesseeOperatingLeaseLiabilities
30401000 USD
CY2019Q3 supn Operating Lease Fixed Lease Cost
OperatingLeaseFixedLeaseCost
1498000 USD
supn Operating Lease Fixed Lease Cost
OperatingLeaseFixedLeaseCost
3517000 USD
CY2019Q3 supn Operating Lease Variable Lease Cost
OperatingLeaseVariableLeaseCost
484000 USD
supn Operating Lease Variable Lease Cost
OperatingLeaseVariableLeaseCost
1467000 USD
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1982000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
4984000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
4048000 USD
supn Operating Leases Rent Payments
OperatingLeasesRentPayments
4017000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
31856000 USD
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P13Y5M12D
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0434
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
784000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3089000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2735000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2550000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2537000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
29371000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
41066000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10665000 USD
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
30401000 USD
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
3600000 USD
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2700000 USD
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2700000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3400000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2287000 USD
CY2018Q4 supn Operating Leases Future Minimum Payments Thereafter Due
OperatingLeasesFutureMinimumPaymentsThereafterDue
1840000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
7527000 USD
CY2019Q3 supn Allowance For Expected Sales Deductions
AllowanceForExpectedSalesDeductions
10400000 USD
CY2018Q4 supn Allowance For Expected Sales Deductions
AllowanceForExpectedSalesDeductions
11500000 USD
CY2019Q3 us-gaap Revenues
Revenues
102140000 USD
CY2018Q3 us-gaap Revenues
Revenues
102996000 USD
us-gaap Revenues
Revenues
292309000 USD
us-gaap Revenues
Revenues
292963000 USD
CY2019Q3 supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
1600000 USD
supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
5000000.0 USD
CY2018Q3 supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
1500000 USD
supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
4300000 USD
CY2014Q3 supn Non Recourse Debt Sale Of Future Royalties Noncurrent
NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent
30000000.0 USD

Files In Submission

Name View Source Status
0001356576-19-000045-index-headers.html Edgar Link pending
0001356576-19-000045-index.html Edgar Link pending
0001356576-19-000045.txt Edgar Link pending
0001356576-19-000045-xbrl.zip Edgar Link pending
a3q1910qmdacurrentportfolioa.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
supn-20190930.xsd Edgar Link pending
supn-20190930x10q.htm Edgar Link pending
supn-20190930x10qxex311.htm Edgar Link pending
supn-20190930x10qxex312.htm Edgar Link pending
supn-20190930x10qxex321.htm Edgar Link pending
supn-20190930x10qxex322.htm Edgar Link pending
supn-20190930x10q_htm.xml Edgar Link completed
supn-20190930_cal.xml Edgar Link unprocessable
supn-20190930_def.xml Edgar Link unprocessable
supn-20190930_lab.xml Edgar Link unprocessable
supn-20190930_pre.xml Edgar Link unprocessable